drugset / Trial / NCT00605475
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study was to evaluate, in patients with Type 2 Diabetes Mellitus, whether Canakinumab can lower Glycosylated hemoglobin / hemoglobin A1c (HbA1c) and/or peak glucose levels in response to an oral glucose tolerance test (OGTT).
Timeline
- Start
- 2007-12
- Primary completion
- 2010-09
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Canakinumab | Monoclonal antibody | 0.03 mg/kg | Intravenous |
| Subject | Canakinumab | Monoclonal antibody | 0.1 mg/kg | Intravenous |
| Subject | Canakinumab | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | Canakinumab | Monoclonal antibody | 1.5 mg/kg | Intravenous |
| Subject | Canakinumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Background | Metformin | Small molecule | — | — |